Aruna V Sarma1, James Hotaling2, Rodney L Dunn3, Patricia A Cleary4, Barbara H Braffett4, Catherine Kim5, Catherine Martin5, William Herman5, Patricia Gatcomb6, Alan M Jacobson7, Sarah K Holt8, Hunter Wessells8. 1. Department of Urology, University of Michigan, Ann Arbor, Michigan. Electronic address: asarma@umich.edu. 2. Department of Surgery, University of Utah, Salt Lake City, Utah. 3. Department of Urology, University of Michigan, Ann Arbor, Michigan. 4. The Biostatistics Center, George Washington University, Washington, DC. 5. Department of Medicine, University of Michigan, Ann Arbor, Michigan. 6. Department of Medicine, Yale University, New Haven, Connecticut. 7. Winthrop Research Institute, Winthrop-University Hospital, Mineola, New York. 8. Department of Urology, University of Washington, Seattle, Washington.
Abstract
PURPOSE: Previous studies have revealed lower prostate specific antigen concentrations in men with type 2 diabetes, paralleling the reported lower prevalence of prostate cancer in diabetic men. Data are lacking on prostate specific antigen in men with type 1 diabetes whose insulin and obesity profiles differ from those with type 2 diabetes mellitus. In this study we examined the relationship between long-term glycemic control and prostate specific antigen in men with type 1 diabetes mellitus. MATERIALS AND METHODS:Total prostate specific antigen was measured at one time in 639 men in the EDIC, the observational followup of participants in the DCCT. The relationship between DCCT/EDIC weighted mean hemoglobin A1c and log prostate specific antigen was assessed using linear regression modeling after adjusting for age, body mass index, total testosterone, statin and thiazide medication use, diabetes duration, and DCCT randomization arm and cohort. RESULTS:Median subject age was 52 years, body mass index was 28.4 kg/m(2) and DCCT/EDIC time-weighted hemoglobin A1c was 7.9%. Median prostate specific antigen was 0.64 ng/ml (IQR 0.43, 1.05). Prostate specific antigen increased significantly with age (p <0.0001) and with lower time-weighted hemoglobin A1c (p <0.0001). Each 10% increase in hemoglobin A1c was accompanied by an 11% reduction in prostate specific antigen (p=0.0001). CONCLUSIONS:Prostate specific antigen decreases as hemoglobin A1c increases in men with type 1 diabetes mellitus. This relationship is independent of age, body mass index, androgen levels, medication use and measures of diabetes severity, which suggests that factors related to glycemia may directly affect prostate specific antigen levels.
RCT Entities:
PURPOSE: Previous studies have revealed lower prostate specific antigen concentrations in men with type 2 diabetes, paralleling the reported lower prevalence of prostate cancer in diabeticmen. Data are lacking on prostate specific antigen in men with type 1 diabetes whose insulin and obesity profiles differ from those with type 2 diabetes mellitus. In this study we examined the relationship between long-term glycemic control and prostate specific antigen in men with type 1 diabetes mellitus. MATERIALS AND METHODS: Total prostate specific antigen was measured at one time in 639 men in the EDIC, the observational followup of participants in the DCCT. The relationship between DCCT/EDIC weighted mean hemoglobin A1c and log prostate specific antigen was assessed using linear regression modeling after adjusting for age, body mass index, total testosterone, statin and thiazide medication use, diabetes duration, and DCCT randomization arm and cohort. RESULTS: Median subject age was 52 years, body mass index was 28.4 kg/m(2) and DCCT/EDIC time-weighted hemoglobin A1c was 7.9%. Median prostate specific antigen was 0.64 ng/ml (IQR 0.43, 1.05). Prostate specific antigen increased significantly with age (p <0.0001) and with lower time-weighted hemoglobin A1c (p <0.0001). Each 10% increase in hemoglobin A1c was accompanied by an 11% reduction in prostate specific antigen (p=0.0001). CONCLUSIONS:Prostate specific antigen decreases as hemoglobin A1c increases in men with type 1 diabetes mellitus. This relationship is independent of age, body mass index, androgen levels, medication use and measures of diabetes severity, which suggests that factors related to glycemia may directly affect prostate specific antigen levels.
Authors: David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman Journal: N Engl J Med Date: 2005-12-22 Impact factor: 91.245
Authors: David M Werny; Trevor Thompson; Mona Saraiya; David Freedman; Benny J Kottiri; Robert R German; Mark Wener Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-12-19 Impact factor: 4.254
Authors: Jacques Baillargeon; Brad H Pollock; Alan R Kristal; Patrick Bradshaw; Javier Hernandez; Joseph Basler; Betsy Higgins; Steve Lynch; Thomas Rozanski; Dean Troyer; Ian Thompson Journal: Cancer Date: 2005-03-01 Impact factor: 6.860
Authors: Nelly Pitteloud; Vamsi K Mootha; Andrew A Dwyer; Megan Hardin; Hang Lee; Karl-Fredrik Eriksson; Devjit Tripathy; Maria Yialamas; Leif Groop; Dariush Elahi; Frances J Hayes Journal: Diabetes Care Date: 2005-07 Impact factor: 19.112
Authors: Adedayo A Onitilo; Rachel V Stankowski; Richard L Berg; Jessica M Engel; Ingrid Glurich; Gail M Williams; Suhail A Doi Journal: Eur J Cancer Prev Date: 2014-03 Impact factor: 2.497
Authors: Rachel Dankner; Paolo Boffetta; Lital Keinan-Boker; Ran D Balicer; Alla Berlin; Liraz Olmer; Havi Murad; Barbara Silverman; Moshe Hoshen; Laurence S Freedman Journal: Diabetologia Date: 2016-05-17 Impact factor: 10.122